Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report

Claudia Lucía Sossa Melo; Angela María Peña; Luis Antonio Salazar; Sara Inés Jiménez; Edgar David Gómez; Claudia Marcela Chalela; Miguel Ayala-Castillo; Iván Mauricio Peña

doi:10.1016/j.nmd.2018.11.008

Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report

Claudia Lucía Sossa Melo, Angela María Peña, Luis Antonio Salazar, Sara Inés Jiménez, Edgar David Gómez, Claudia Marcela Chalela, Miguel Ayala-Castillo, Iván Mauricio Peña

Research output: Articles / Notes › Scientific Article › peer-review

21 Scopus citations

Abstract

Myasthenia gravis is a neuromuscular autoimmune disease characterized by fatigable weakness of skeletal muscles that results from an antibody-mediated immunological attack directed at acetylcholine postsynaptic receptors. Autologous hematopoietic stem cell transplantation is considered as a treatment option in refractory cases of myasthenia gravis. A 56-year-old Colombian male presented with six months of progressive hoarseness and dysphagia, with a positive repetitive stimulation test suggestive of end plate neuromuscular disease. Myasthenia gravis was confirmed with serology testing that reported presence of circulating acetylcholine postsynaptic receptors antibodies. The patient received several lines of pharmacological treatment and thymectomy without control of symptoms, requiring admission to the intensive care unit and mechanical ventilation in two occasions. Patient underwent autologous hematopoietic stem cell transplantation and has been in complete clinical remission for 65 months. Hematopoietic stem cell transplantation is a well-tolerated treatment that should be considered over conventional therapy in selected patients with refractory myasthenia gravis.

Original language	English
Pages (from-to)	142-145
Number of pages	4
Journal	Neuromuscular Disorders
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/j.nmd.2018.11.008
State	Published - Feb 2019

Keywords

Autologous hematopoietic stem cell transplantation
Miastenia gravis
Refractory
Treatment

Access to Document

10.1016/j.nmd.2018.11.008

Cite this

@article{8cce5ba7457b4105937712902648fe03,

title = "Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report",

abstract = "Myasthenia gravis is a neuromuscular autoimmune disease characterized by fatigable weakness of skeletal muscles that results from an antibody-mediated immunological attack directed at acetylcholine postsynaptic receptors. Autologous hematopoietic stem cell transplantation is considered as a treatment option in refractory cases of myasthenia gravis. A 56-year-old Colombian male presented with six months of progressive hoarseness and dysphagia, with a positive repetitive stimulation test suggestive of end plate neuromuscular disease. Myasthenia gravis was confirmed with serology testing that reported presence of circulating acetylcholine postsynaptic receptors antibodies. The patient received several lines of pharmacological treatment and thymectomy without control of symptoms, requiring admission to the intensive care unit and mechanical ventilation in two occasions. Patient underwent autologous hematopoietic stem cell transplantation and has been in complete clinical remission for 65 months. Hematopoietic stem cell transplantation is a well-tolerated treatment that should be considered over conventional therapy in selected patients with refractory myasthenia gravis.",

keywords = "Autologous hematopoietic stem cell transplantation, Miastenia gravis, Refractory, Treatment",

author = "{Sossa Melo}, {Claudia Luc{\'i}a} and Pe{\~n}a, {Angela Mar{\'i}a} and Salazar, {Luis Antonio} and Jim{\'e}nez, {Sara In{\'e}s} and G{\'o}mez, {Edgar David} and Chalela, {Claudia Marcela} and Miguel Ayala-Castillo and Pe{\~n}a, {Iv{\'a}n Mauricio}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier B.V.",

year = "2019",

month = feb,

doi = "10.1016/j.nmd.2018.11.008",

language = "Ingl{\'e}s",

volume = "29",

pages = "142--145",

journal = "Neuromuscular Disorders",

issn = "0960-8966",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis

T2 - A case report

AU - Sossa Melo, Claudia Lucía

AU - Peña, Angela María

AU - Salazar, Luis Antonio

AU - Jiménez, Sara Inés

AU - Gómez, Edgar David

AU - Chalela, Claudia Marcela

AU - Ayala-Castillo, Miguel

AU - Peña, Iván Mauricio

PY - 2019/2

Y1 - 2019/2

N2 - Myasthenia gravis is a neuromuscular autoimmune disease characterized by fatigable weakness of skeletal muscles that results from an antibody-mediated immunological attack directed at acetylcholine postsynaptic receptors. Autologous hematopoietic stem cell transplantation is considered as a treatment option in refractory cases of myasthenia gravis. A 56-year-old Colombian male presented with six months of progressive hoarseness and dysphagia, with a positive repetitive stimulation test suggestive of end plate neuromuscular disease. Myasthenia gravis was confirmed with serology testing that reported presence of circulating acetylcholine postsynaptic receptors antibodies. The patient received several lines of pharmacological treatment and thymectomy without control of symptoms, requiring admission to the intensive care unit and mechanical ventilation in two occasions. Patient underwent autologous hematopoietic stem cell transplantation and has been in complete clinical remission for 65 months. Hematopoietic stem cell transplantation is a well-tolerated treatment that should be considered over conventional therapy in selected patients with refractory myasthenia gravis.

AB - Myasthenia gravis is a neuromuscular autoimmune disease characterized by fatigable weakness of skeletal muscles that results from an antibody-mediated immunological attack directed at acetylcholine postsynaptic receptors. Autologous hematopoietic stem cell transplantation is considered as a treatment option in refractory cases of myasthenia gravis. A 56-year-old Colombian male presented with six months of progressive hoarseness and dysphagia, with a positive repetitive stimulation test suggestive of end plate neuromuscular disease. Myasthenia gravis was confirmed with serology testing that reported presence of circulating acetylcholine postsynaptic receptors antibodies. The patient received several lines of pharmacological treatment and thymectomy without control of symptoms, requiring admission to the intensive care unit and mechanical ventilation in two occasions. Patient underwent autologous hematopoietic stem cell transplantation and has been in complete clinical remission for 65 months. Hematopoietic stem cell transplantation is a well-tolerated treatment that should be considered over conventional therapy in selected patients with refractory myasthenia gravis.

KW - Autologous hematopoietic stem cell transplantation

KW - Miastenia gravis

KW - Refractory

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85059677957&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2018.11.008

DO - 10.1016/j.nmd.2018.11.008

M3 - Artículo Científico

C2 - 30639064

AN - SCOPUS:85059677957

SN - 0960-8966

VL - 29

SP - 142

EP - 145

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - 2

ER -

Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this